A Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Ineligible Multiple Myeloma

We sought a regimen that incorporates optimal novel agents in transplant-ineligible patients that balances efficacy with toxicity. Our study evaluated modified lenalidomide-bortezomib-dexamethasone (RVD lite) in this population. RVD lite was administered over a 35-day cycle. Lenalidomide 15 mg was g...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Haematol
Autori principali: O’Donnell, Elizabeth K., Laubach, Jacob P., Yee, Andrew J., Chen, Tianqi, Huff, Carol Ann, Basile, Frank G., Wade, Philip M., Paba-Prada, Claudia E., Ghobrial, Irene M., Schlossman, Robert L., Burke, Jill N., Harrington, Cynthia C., Lively, Kathleen J., Lyons, Hannah F., Munshi, Nikhil C., Anderson, Kenneth C., Trippa, Lorenzo, Richardson, Paul G., Raje, Noopur S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6074026/
https://ncbi.nlm.nih.gov/pubmed/29740809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15261
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi